Achilles Therapeutics plc (NASDAQ:ACHL) Sees Significant Increase in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 122,300 shares, an increase of 35.4% from the December 31st total of 90,300 shares. Based on an average trading volume of 169,400 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.3% of the company’s shares are short sold.

Achilles Therapeutics Price Performance

Shares of ACHL stock opened at $1.12 on Friday. The stock has a market cap of $46.03 million, a PE ratio of -0.68 and a beta of 1.32. The stock has a 50-day moving average of $1.10 and a 200-day moving average of $0.96. Achilles Therapeutics has a one year low of $0.63 and a one year high of $1.76.

Hedge Funds Weigh In On Achilles Therapeutics

A hedge fund recently raised its stake in Achilles Therapeutics stock. BML Capital Management LLC lifted its holdings in Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,100,002 shares of the company’s stock after purchasing an additional 3,474,828 shares during the quarter. Achilles Therapeutics comprises 2.5% of BML Capital Management LLC’s holdings, making the stock its 11th biggest position. BML Capital Management LLC owned approximately 9.98% of Achilles Therapeutics worth $4,182,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.38% of the company’s stock.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.